Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

<p>Figure S4 shows the gating strategy of monocytes sorted from BAFF-expressing and control tumors</p>

Збережено в:

Бібліографічні деталі
Автор:	Wei Liu (20030) (author)
Інші автори:	Paweł Stachura (8480817) (author), Haifeng C. Xu (7373933) (author), Renáta Váraljai (15194397) (author), Prashant Shinde (3707917) (author), Nikkitha Umesh Ganesh (15194400) (author), Matthias Mack (148002) (author), Anke Van Lierop (15194403) (author), Anfei Huang (461244) (author), Balamurugan Sundaram (440602) (author), Karl S. Lang (8444004) (author), Daniel Picard (14938665) (author), Ute Fischer (15194406) (author), Marc Remke (3508145) (author), Bernhard Homey (31953) (author), Alexander Roesch (2416078) (author), Dieter Häussinger (15194409) (author), Philipp A. Lang (7373936) (author), Arndt Borkhardt (2891) (author), Aleksandra A. Pandyra (8444013) (author)
Опубліковано:	2025
Предмети:	Cancer Tumor Biology Immuno-oncology Immunology Cytokines Myeloid-derived suppressor cells NK cells Tumor immunology animal models Tumor-associated macrophages Skin Cancers Melanoma Tumor Microenvironment Cytokines and the microenvironment
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Figure 6 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Figure7 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Table 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Table 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary Table 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
за авторством: Wei Liu (20030)
Опубліковано: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
за авторством: Daniel S. Green (15047598)
Опубліковано: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
за авторством: Robin M. Hallett (15037427)
Опубліковано: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
за авторством: Robin M. Hallett (15037427)
Опубліковано: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
за авторством: Sonia A. Patel (15055688)
Опубліковано: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
за авторством: Sonia A. Patel (15055688)
Опубліковано: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
за авторством: Sonia A. Patel (15055688)
Опубліковано: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
за авторством: Sonia A. Patel (15055688)
Опубліковано: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
за авторством: Sonia A. Patel (15055688)
Опубліковано: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
за авторством: Dahihm Kim (16546203)
Опубліковано: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
за авторством: Alexander N. Shoushtari (15023909)
Опубліковано: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
за авторством: Min Wu (14962986)
Опубліковано: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
за авторством: Min Wu (14962986)
Опубліковано: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
за авторством: Min Wu (14962986)
Опубліковано: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
за авторством: Min Wu (14962986)
Опубліковано: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
за авторством: Defne Bayik (14961098)
Опубліковано: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
за авторством: James S. Wilmott (15008931)
Опубліковано: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
за авторством: James S. Wilmott (15008931)
Опубліковано: (2025)

Supplementary file 1_Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.docx
за авторством: Wenjia Ge (22687361)
Опубліковано: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_h8gffvv4fcgse0m46oskl50q7r